Journal for ImmunoTherapy of Cancer (Nov 2021)
422 Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients with urothelial carcinoma
- Paul Young,
- Erol Wiegert,
- Tanner Miest,
- Bradley Leibovich,
- Stephen Bardot,
- Stephen Boorjian,
- Mark Gonzalgo,
- Loren Herrera-Hernandez,
- Matthew Tollefson,
- Jeffrey Karnes,
- Paige Nichols,
- Tessa Kroeninger,
- Rachel Graham,
- Carole Lahana,
- Monica Reckner,
- Alysha Newsom,
- Nandakumar Packiriswamy,
- Janice Anoka,
- Kah Whye Peng,
- Alice Bexon,
- Shruthi Naik
Affiliations
- Paul Young
- The Intensive Care Research Programme, Medical Research Institute of New Zealand, Wellington, New Zealand
- Erol Wiegert
- 8Bexon Clinical Consulting, Upper Montclair, USA
- Tanner Miest
- 1University of Texas and Mayo Clinic, Houston, TX, USA
- Bradley Leibovich
- 2Mayo Clinic, Rochester, MN, USA
- Stephen Bardot
- 3Ochsner Clinic, New Orleans, LA, USA
- Stephen Boorjian
- 2Mayo Clinic, Rochester, MN, USA
- Mark Gonzalgo
- 4University of Miami, Miami, FL, USA
- Loren Herrera-Hernandez
- 2Mayo Clinic, Rochester, MN, USA
- Matthew Tollefson
- 2Mayo Clinic, Rochester, MN, USA
- Jeffrey Karnes
- 2Mayo Clinic, Rochester, MN, USA
- Paige Nichols
- 2Mayo Clinic, Rochester, MN, USA
- Tessa Kroeninger
- 2Mayo Clinic, Rochester, MN, USA
- Rachel Graham
- 3Ochsner Clinic, New Orleans, LA, USA
- Carole Lahana
- 4University of Miami, Miami, FL, USA
- Monica Reckner
- 5Vyriad, Inc., Rochester, MN, USA
- Alysha Newsom
- 2Mayo Clinic, Rochester, MN, USA
- Nandakumar Packiriswamy
- 6Mayo Clinic and Vyriad Inc., Rochester, MN, USA
- Janice Anoka
- 7Vyriad Inc., Rochester, MN, USA
- Kah Whye Peng
- 2Mayo Clinic, Rochester, MN, USA
- Alice Bexon
- 7Vyriad Inc., Rochester, MN, USA
- Shruthi Naik
- 6Mayo Clinic and Vyriad Inc., Rochester, MN, USA
- DOI
- https://doi.org/10.1136/jitc-2021-SITC2021.422
- Journal volume & issue
-
Vol. 9,
no. Suppl 2
Abstract
No abstracts available.